115 related articles for article (PubMed ID: 8647655)
1. Oxytocin and oxytocin-analogue F314 inhibit cell proliferation and tumor growth of rat and mouse mammary carcinomas.
Cassoni P; Sapino A; Papotti M; Bussolati G
Int J Cancer; 1996 Jun; 66(6):817-20. PubMed ID: 8647655
[TBL] [Abstract][Full Text] [Related]
2. Oxytocin inhibits proliferation of human breast cancer cell lines.
Cassoni P; Sapino A; Negro F; Bussolati G
Virchows Arch; 1994; 425(5):467-72. PubMed ID: 7850070
[TBL] [Abstract][Full Text] [Related]
3. Oxytocin receptor within the breast: biological function and distribution.
Sapino A; Cassoni P; Stella A; Bussolati G
Anticancer Res; 1998; 18(3C):2181-6. PubMed ID: 9703781
[TBL] [Abstract][Full Text] [Related]
4. Effect of serial passage in nude athymic mice on the growth characteristics and chemotherapy responsiveness of 13762 and R3230AC mammary tumor xenografts.
Bogden AE; Kelton DE; Cobb WR; Gulkin TA; Johnson RK
Cancer Res; 1978 Jan; 38(1):59-64. PubMed ID: 618583
[No Abstract] [Full Text] [Related]
5. The novel tubulin-binding drug BTO-956 inhibits R3230AC mammary carcinoma growth and angiogenesis in Fischer 344 rats.
Shan S; Lockhart AC; Saito WY; Knapp AM; Laderoute KR; Dewhirst MW
Clin Cancer Res; 2001 Aug; 7(8):2590-6. PubMed ID: 11489843
[TBL] [Abstract][Full Text] [Related]
6. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models.
Tejeda M; Gaál D; Hullán L; Hegymegi-Barakonyi B; Kéri G
Anticancer Res; 2006; 26(5A):3477-83. PubMed ID: 17094470
[TBL] [Abstract][Full Text] [Related]
8. Antitumor and chemopreventive effects of a clomiphene analog, MDL 103,323, in mammary carcinoma.
Bitonti AJ; Baumann RJ; Bush TL; Cashman EA; Wright CL; Prakash NJ
Anticancer Res; 1996; 16(5A):2553-7. PubMed ID: 8917350
[TBL] [Abstract][Full Text] [Related]
9. Oxytocin inhibits the progression of human ovarian carcinoma cells in vitro and in vivo.
Morita T; Shibata K; Kikkawa F; Kajiyama H; Ino K; Mizutani S
Int J Cancer; 2004 Apr; 109(4):525-32. PubMed ID: 14991573
[TBL] [Abstract][Full Text] [Related]
10. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity.
Teplán I
Acta Biol Hung; 2000; 51(1):1-29. PubMed ID: 10866357
[TBL] [Abstract][Full Text] [Related]
11. Tranilast inhibits the growth and metastasis of mammary carcinoma.
Chakrabarti R; Subramaniam V; Abdalla S; Jothy S; Prud'homme GJ
Anticancer Drugs; 2009 Jun; 20(5):334-45. PubMed ID: 19322072
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of edotecarin in breast carcinoma models.
Ciomei M; Croci V; Stellari F; Amboldi N; Giavarini R; Pesenti E
Cancer Chemother Pharmacol; 2007 Jul; 60(2):229-35. PubMed ID: 17089166
[TBL] [Abstract][Full Text] [Related]
13. [Preclinical screening of chemotherapeutic and endocrine agents using human tumor xenografts--nude mouse system].
Kubota T; Ishibiki K; Abe O
Gan To Kagaku Ryoho; 1991 Jul; 18(9):1439-47. PubMed ID: 1854214
[TBL] [Abstract][Full Text] [Related]
14. Effects of epithelial growth factor receptor (EGFR) kinase inhibitors on genetically reconstituted mouse mammary glands.
Roth DR; Roman D; Cozens R; Brandt R; Seewald W; Greiner B; Wenger F; Mamom T; Germann PG
Exp Toxicol Pathol; 2003 Nov; 55(4):237-45. PubMed ID: 14703768
[TBL] [Abstract][Full Text] [Related]
15. Oxytocin enhances myoepithelial cell differentiation and proliferation in the mouse mammary gland.
Sapino A; Macrì L; Tonda L; Bussolati G
Endocrinology; 1993 Aug; 133(2):838-42. PubMed ID: 8344220
[TBL] [Abstract][Full Text] [Related]
16. Human chorionic gonadotropin inhibits N-Methyl-N-nitrosourea-induced mammary carcinoma growth in female Lewis rats.
Yuri T; Lai YC; Yoshizawa K; Tsubura A
In Vivo; 2012; 26(3):361-7. PubMed ID: 22523287
[TBL] [Abstract][Full Text] [Related]
17. Biological relevance of oxytocin and oxytocin receptors in cancer cells and primary tumors.
Cassoni P; Marrocco T; Deaglio S; Sapino A; Bussolati G
Ann Oncol; 2001; 12 Suppl 2():S37-9. PubMed ID: 11762350
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of cryptophycins: effect of infusion time and combination studies.
Menon K; Alvarez E; Forler P; Phares V; Amsrud T; Shih C; Al-Awar R; Teicher BA
Cancer Chemother Pharmacol; 2000; 46(2):142-9. PubMed ID: 10972484
[TBL] [Abstract][Full Text] [Related]
19. Embryonal mass and hormone-associated effects of pregnancy inducing a differential growth of four murine tumors.
Bustuoabad OD; di Gianni PD; Franco M; Kordon EC; Vanzulli SI; Meiss RP; Grion LC; Díaz GS; Nosetto SH; Hockl P; Lombardi MG; Pasqualini CD; Ruggiero RA
Oncol Res; 2002; 13(3):147-60. PubMed ID: 12549624
[TBL] [Abstract][Full Text] [Related]
20. Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents.
Brandt R; Wong AM; Hynes NE
Oncogene; 2001 Sep; 20(39):5459-65. PubMed ID: 11571643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
